Use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease in China: A retrospective cohort study

Jian-Qing Tian [*1], Yu-Hao Lin [*1], Zhi-Jun Zhang [1], Yi-Ting Peng [2], Jia-Wen Ye [1], Zhi-Yi Wang [1]

Running Head: use of cardiovascular preventive therapies

Correspondence to Professor Jian-Qing Tian; 449256119@qq.com

[*]Jian-Qing Tian and Yu-Hao Lin have contributed equally to this work.

[1]Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.

[2]Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China.

Authors' information: names, affiliations and e-mail addresses:

Jian-Qing Tian: Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.

E-mail: 449256119@qq.com

Yu-Hao Lin: Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.

E-mail: tzlinyuhao@163.com

Zhi-Jun Zhang: Department of Endocrinology, Xiamen Humanity Hospital, Fujian

Medical University, Xiamen, Fujian, China.

E-mail: zzjlsyz@163.com

Yi-Ting Peng: Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China.

E-mail: 1368941124@qq.com

Jia-Wen Ye: Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.

E-mail: kavin2021@126.com

Zhi-Yi Wang: Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.

E-mail: 951482925@qq.com

ABSTRACT

Aims

To examine trends of glucose-, blood pressure-, and lipid-lowering drugs and antiplatelet medications with cardiovascular benefit in type 2 diabetes (T2DM) patients with established or high risk of atherosclerotic cardiovascular disease (ASCVD).

Materials and methods

In this retrospective cohort study, we identified T2DM patients with established or high risk of ASCVD using diagnostic codes from the institutional data of Xiamen Humanity Hospital between 2018 and 2023. The prescription of any of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) or sodium glucose cotransporter-2 inhibitors (SGLT2i), angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB), moderate-intensity statins, and aspirin was quantified using frequencies/percentages.

Results

We identified 17,320 patients with T2DM and established or high risk of ASCVD, with a mean of 66.3 years and 43.9% of patients were women. From 2018 to 2023, the use of GLP-1 RA increased from 2.7% to 13.7%; SGLT2i increased from 3.9% to 16.5%; ACEI/ARB increased from 28.1% to 43.0%; moderate-intensity statins increased from 61.6% to 70.5%; and aspirin increased from 23.7% to 32.9%. Overall, only 4.8% of patients were prescribed 4 evidence-based cardiovascular preventive therapies, and 17.6% of patients were not prescribed any of these medications.

Conclusions

This study demonstrated that despite a modest annual increase in the use of evidence-based cardiovascular preventive medications among patients with T2DM and established or high risk of ASCVD, less than 1 in 20 patients received all 4 medications. To maximize the potential population benefit of these therapies, further efforts are necessary on many fronts.

Keywords: type 2 diabetes, atherosclerotic cardiovascular disease, real-world evidence, pharmaco-epidemiology, observational study

Significance of this study.

What is already known about this subject?

There is a significant gap in evidence-based therapy and clinical application of guidelines for patients with type 2 diabetes and atherosclerotic cardiovascular disease.

The use of evidence-based therapy in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease in China remains unknown.

What are the new findings?

Type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease remain undertreated with evidence-based therapies.

The usage of evidence-based therapy in type 2 patients with high risk of atherosclerotic cardiovascular disease is lower than patients with established atherosclerotic cardiovascular disease.

How might these results change the focus of research or clinical practice?

Creative implementation science approaches will be necessary to further increase the use of these evidence-based therapy in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease.

INTRODUCTION

Type 2 diabetes (T2DM) is a major risk factor for the development of atherosclerotic cardiovascular disease (ASCVD), which is the leading cause of death and long-term complications in T2DM.[1] A systematic review demonstrated that the prevalence of ASCVD in patients with T2DM was nearly 30%, and up to two-thirds of T2DM patients will develop ASCVD during their lifetimes.[2,3] Therefore, there is an urgent need to initiate and intensify secondary preventive to reduce the risk of recurrent cardiovascular events and cardiovascular mortality in patients with T2DM and ASCVD.

Although, the US Food and Drug Administration (FDA) conducted randomized cardiovascular outcome trials (CVOTs) for all glucose–lowering medications in 2008, the cardiovascular benefit of these medications was controversial until 2015. The glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown benefit toward for secondary prevention of ASCVD.[4] Most importantly, large CVOTs of GLP-1 RA and SGLT2i have shown that these drug classes substantially decrease the risk of cardiovascular events and cardiovascular-related mortality.[5-11] What's more, numerous studies have proved the beneficial effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptor blockers (ARBs), statins, and aspirin therapy on ASCVD outcomes.[12,13] Given these accumulating evidences, the American Diabetes Association (ADA) and the Chinese Diabetes Society recommends the cardio-protective glucose-lowering drug classes (GLP-1 RA and SGLT2i), ACEI/ARB,

statins, and aspirin for comprehensive cardiovascular risk reduction in adults with T2DM and established or high risk of ASCVD.[14,15] Despite these guidelines recommend the GLP-1 RA, SGLT2i, ACEI, ARB, statins, and aspirin for their cardioprotective effects, a degree of therapeutic inertia in clinical practice may be observed for a variety of reasons.

Previous observational studies evaluating individuals with T2DM and ASCVD demonstrate that the use rate of either GLP-1 RA and/or SGLT2i was from 6.7% to 23.2%, either ACEI or ARB was from 53.1% to 72.0%, and high-intensity statins were from 24.7% to 45.4%.[16-19] Due to the differences in included patient characteristics, data sources, and medicines prices, the magnitude of these estimates varied significantly. Furthermore, there is a paucity of contemporary data regarding the use of these agents among patients with T2DM and established or high risk of ASCVD in China. Accurately determining the gaps in evidence-based therapy is essential to disseminate and promote clinical application of guidelines. Thus, our primary aim was to describe the use of either GLP-1 RA and/or SGLT2i, ACEI/ARB, moderate-intensity statins, and aspirin in T2DM individuals with established or high risk of ASCVD during the period 2018 to 2023.

RESEARCH DESIGN AND METHODS

Study design and data source

This study was a population-based retrospective cohort study. The source population consisted of all outpatients who visited in the Xiamen Humanity Hospital, Fujian Medical University, between 2018 and 2023. Informed consent was waived because

the database used in this cohort only contains deidentified information on individuals. The study protocol was approved by the Xiamen Humanity Hospital Ethics Committee (no. HAXM-MEC-20240 820-048-01). The study was conducted according to the ethical principles of the Declaration of Helsinki.

Study population

The study population included adults (age ≥ 18 years) who were diagnosed with T2DM between 2018 and 2023. Disease information was identified using the International Statistical Classification of Diseases, Tenth Revision (ICD-10) (eTable 1). Patients younger than 30 at the time of initial insulin prescription were excluded as they were likely to be type 1 diabetes patients. ICD-10 diagnosis codes were utilized to identify T2DM patients at high cardiovascular risk, which include patients with concomitant ASCVD or high risk of ASCVD. Briefly, ASCVD was defined as having a history of coronary artery disease (previous prior myocardial infarction, unstable angina), peripheral arterial disease (amputation due to poor circulation), cerebrovascular disease (stroke, or transient ischemic attack), or any revascularization intervention. Patients at high risk of ASCVD were defined as those aged ≥ 55 years with two or more risk factors. Risk factors included obesity (body mass index [BMI] ≥ 28 kg/m2), hypertension, smoking, dyslipidemia, and albuminuria.[20] In addition, age, height, weight, and history of smoking were obtained from an electronic medical record. History of hypertension and dyslipidemia were identified by the presence of ICD-10 diagnosis codes. Albuminuria was defined as urine albumin-to-creatinine ratio ≥ 30 mg/g. Patients with longitudinal follow-up may be included in multiple years but

only once per year. Within a given year, only patients with at least 1 glucose-lowering medication record were included. If a patient had multiple visits within a specific year, only the last visit was included in the analysis. Patients with end-stage kidney disease or limited life expectancy were excluded. Additionally, each patient was required to have at least 1 year of follow-up. Consequently, the last date for patient inclusion was 31 December 2023.

Study Outcomes

We ascertained that the primary outcome was the use of cardioprotective glucose-lowering, blood-pressure-lowering, and lipid-lowering pharmacotherapies, and aspirin therapy in T2DM patients with established or high risk of ASCVD. The use of these medications was assessed through the day of the last dispensed prescription within a given year. The prescribed cardioprotective glucose-lowering pharmacotherapy included GLP-1 RA (e.g., semaglutide, dulaglutide, liraglutide, and lixisenatide) and SGLT2i (e.g., empagliflozin, dapagliflozin, and canagliflozin). Prescribed blood pressure-lowering pharmacotherapy included ACEI (e.g., captopril, benazepril, and so on), ARB (e.g., valsartan, irbesartan, and so on), and statins (atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin).

Covariates

Demographic characteristics, such as age, sex, and date of birth were described. Clinical characteristics included glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and BMI. For patients with multiple measurements within a given year, only the last one was used. The co-morbidities (hypertension,

dyslipidemia, and nonalcoholic fatty liver disease) and diabetes chronic complications (retinopathy, neuropathy, and nephropathy) were identified using the ICD-10 code. Concomitant use of oral anti-diabetic, antihypertensive, and lipid-lowering medications was assessed.

Composite Score for Evidence-based Therapy

Evidence-based therapy was defined as the use of either a GLP-1 RA and/or SGLT2i, either an ACEI or ARB, a moderate-intensity statins, and an aspirin. Although high-dose statins are important to prevent cardiovascular events, it is intolerable for most of Chinese populations. Therefore, moderate-intensity statins are recommended as the first choice lipid-lowering drugs by the Endocrinology and Metabolism Physician Branch of the Chinese Medical Doctor Association.[21] Patients in this cohort were deemed to meet the criteria for all four components and were assigned a composite score ranging from 0 to 4, indicating the number of evidence-based therapies prescribed.

Statistical Analysis

Demographic and clinical characteristics, co-morbidities, and concomitant medications were presented as with means ± standard deviations (SDs) for continuous variables and frequency/percentages for categorical variables. The number and proportion of patients with T2DM and established or high risk of ASCVD who received GLP-1 RA and/or SGLT2i, ACEI/ARB, moderate-intensity statins, and aspirin were evaluated annually. All data where necessary were conducted to calculate 95% confidence interval (CI). Statistical comparisons baseline characteristics between

the different groups were using the independent-sample t test for continuous variables and $\chi 2$ test or Fisher's exact test for categorical variables. Two-sided *P* values $<$ 0.05 were considered statistically significant. All analyses were performed using R version 4.4.2 (R Foundation).

RESULTS

Study Participants

We identified 8,418 patients (48.6%) with a dual diagnosis of T2DM and ASCVD and 8,902 patients (51.4%) with T2DM and high risk of ASCVD between 2018 and 2023. These two sub-cohorts thus formed the source of our study population. Among patients with T2DM and ASCVD, 6,776 patients had coronary artery disease, 1,869 patients had cerebrovascular disease, and 3,392 patients had peripheral arterial disease. In the study population, 7,603 patients were female, with a mean age of 66.3 years (SD 10.2). The mean HbA1c level was 7.7% (SD: 1.8), mean LDL-C was 2.8 mmol/L (SD: 1.0), and mean BMI was 28.5 kg/m² (SD: 4.9).

Use Ratios

Overall, the utilization of glucose-lowering drugs with documented cardiovascular benefits was low; however, the rate increased annually from 2018 to 2023 (GLP-1 RA: from 2.7% [73 of 2,720] to 13.7% [439 of 3,200]; SGLT2i: from 3.9% [107 of 2720] to 16.5% [529 of 3200]). Combined, the percentage of patients with T2DM and established or high risk of ASCVD taking either agent increased from 5.7% (156 of 2,720) in 2018 to 21.0% (671 of 3200) in 2023 (Fig. 1). Metformin use was

essentially unchanged over this time (61.3% [1667 of 2,720] in 2018 vs 60.8% [1,945 of 3,200] in 2023). Use of noncardiovascular glucose-lowering agents exhibited a variable decline, including alpha-glucosidase inhibitors (30.1% [818 of 2,720] to 22.2% [709 of 3,200]) and dipeptidyl peptidase-4 inhibitors (DPP-4i) (25.5% [694 of 2,720] to 20.8% [665 of 3,200]), although these medications remained more commonly used than SGLT2i or GLP-1 RAs through 2023（eFigure 1). Of the antihypertensive medications, the use of ACEI/ARB was increased from 28.1% [764 of 2,720] to 43.0% [1,377 of 3,200], while the use of calcium channel blockers was decreased (44.2% [1,202 of 2,720] to 41.8% [1,336 of 3,200]) from 2018 to 2023（eFigure 2). The use of moderate-intensity statins (61.6% [1,676 of 2,720] to 70.5% [2,255 of 3,200]) and aspirin (23.7% [645 of 2,720] to 32.9% [1,053 of 3,200]) pharmacotherapy variably increased (eFigure 3 and Figure 1). In patients with high risk of ASCVD, GLP-1 RA (6.4% [573 of 8,902] vs 8.9% [748 of 8,418]), SGLT2i (8.6% [768 of 8,902] vs 12.4% [1,046 of 8,418]), ACEI/ARB (31.0% [2,752 of 8,902] vs 40.4% [3,405 of 8,418]), moderate-intensity statins (52.3% [4,659 of 8,902] vs 81.0% [6,817 of 8,418]), and aspirin (11.5% [1,028 of 8,902] vs 46.8% [3,937 of 8,418]) showed lower usage rates than patients with ASCVD (Figure 2).

Evidence-based Therapy

Compared with the overall cohort, patients prescribed GLP-1RA or SGLT2i were younger (mean age: GLP-1 RA: 61.1 years; SGLT2i: 63.0 years; overall: 66.3 years), were fatter (mean BMI: GLP-1 RA: 30.2 kg/m2; SGLT2i, 29.6 kg/m2; overall: 28.5 kg/m2), had a lower percentage of patients with HbA1c < 7% (GLP-1 RA: 33.5%;

SGLT2i: 36.6%; overall: 41.1%), had higher prevalence of ASCVD (GLP-1 RA: 56.6%; SGLT2i: 57.7%; overall: 48.6%), had lower prevalence of heart failure (GLP-1 RA: 11.5%; SGLT2i: 9.6%; overall: 16.3%), had higher prevalence of dyslipidemia (GLP-1 RA: 61.5%; SGLT2i: 59.9%; overall: 50.9%) and nonalcoholic fatty liver disease (GLP-1 RA: 31.6%; SGLT2i: 21.1%; overall: 17.4%). Patients who prescribed a GLP-1 RA had higher prevalence of diabetes chronic complications (retinopathy: 13.4% vs 8.0%; neuropathy: 45.6% vs 19.2%; nephropathy: 24.5%vs 15.7%) compared with the overall cohort. Patients who prescribed an SGLT2i had similar rates of diabetic retinopathy and diabetic nephropathy yet were more likely to had diabetic neuropathy compared to the overall cohort (neuropathy: 26.0% vs 19.2%). Patients who prescribed a GLP-1 RA, compared with those who prescribed an SGLT2i, were fatter (mean BMI: 30.2 kg/m2 vs 29.6 kg/m2). Of note, diabetes chronic complications (retinopathy: 13.4% vs 8.4%; neuropathy: 45.6% vs 26.0%; nephropathy: 24.5% vs 17.1%) were more common among those prescribed a GLP-1 RA than those prescribed an SGLT2i (Table 1). The demographics of participants prescribed an ACEI or ARB were similar to those of the overall cohort. Patients receiving an ACEI or ARB were more likely to have peripheral artery disease (43.4% vs 40.3%), cerebrovascular disease (24.3% vs 22.2%), and hypertension (90.1% vs 66.6%) compared to the overall cohort. Patients prescribed ACEI or ARB exhibited a higher prevalence of diabetes chronic complications compared to the overall cohort (retinopathy: 11.2% vs 8.0%; neuropathy: 22.9% vs 19.2%; nephropathy: 22.5% vs 15.7%) (Table 1).

Table 1. Patient characteristics at baseline, mean (SD) or n (%) by individual evident-based therapy.

	Patients, % (95% CI)					
		Therapy prescription				
Patient characteristics	Overall (N = 17320)	GLP-1 RA (N = 1321)	SGLT-2i (N = 1814)	ACEI/ARB (N = 6157)	moderate-intensity statin (N = 11476)	Aspirin (N = 4965)
Age, mean (SD) [95% CI], y	66.3 (10.2) [66.1-66.5]	61.1 (11.2) *† [60.5-61.7]	63.0 (8.4) *† [62.6-63.4]	67.0 (10.1) * [66.7-67.3]	66.2 (10.2) [66.0-66.4]	65.4 (10.0) * [65.1-65.7]
Sex						
Men	56.1 (55.4-56.8)	58.9 (56.2-61.6) †	53.8 (51.5-56.1) †	56.8 (55.6-58.0)	56.9 (56.0-57.8)	63.3 (62.0-64.6) *
Women	43.9 (43.2-44.6)	41.1 (38.4-43.8) †	46.2 (43.9-48.5) †	43.2 (42.0-44.4)	43.1 (42.2-44.0)	36.7 (35.4-38.0) *
Birth quarter						
1	22.5 (21.9-23.1)	23.6 (21.3-25.9)	22.9 (21.0-24.8)	22.8 (21.8-23.8)	22.7 (21.9-23.5)	22.5 (21.3-23.7)
2	22.3 (21.7-22.9)	22.4 (20.2-24.6)	23.2 (21.3-25.1)	20.8 (19.8-21.8)	21.9 (21.1-22.7)	21.3 (20.2-22.4)
3	25.9 (25.2-26.6)	26.8 (24.4-29.2)	26.0 (24.0-28.0)	26.1 (25.0-27.2)	25.0 (24.2-25.8)	24.8 (23.6-26.0)
4	29.2 (28.5-29.9)	27.2 (24.8-29.6)	27.9 (25.8-30.0)	30.4 (29.3-31.5)	30.5 (29.7-31.3)	31.4 (30.1-32.7) *
ASCVD	48.6 (47.9-49.3)	56.6 (53.9-59.3) *	57.7 (55.4-60.0) *	55.3 (54.1-56.5) *	59.4 (58.5-60.3) *	79.3 (78.2-80.4) *
Coronary artery disease‡	80.5 (79.7-81.3)	76.1 (73.0-79.2) *	79.7 (77.3-82.1)	78.2 (76.8-79.6) *	85.8 (85.0-86.6) *	81.4 (80.2-82.6)
Cerebrovascular disease‡	22.2 (21.3-23.1)	20.9 (18.0-23.8)	19.9 (17.5-22.3)	24.3 (22.9-25.7) *	26.7 (25.6-27.8) *	23.7 (22.4-25.0)
Peripheral arterial disease‡	40.3 (39.3-41.3)	44.4 (40.8-48.0) *	40.9 (37.9-43.9)	43.4 (41.7-45.1) *	41.3 (40.1-42.5)	35.6 (34.1-37.1) *
Comorbidities						
Heart failure	16.3 (15.7-16.9)	11.5 (9.8-13.2) *	9.6 (8.2-11.0) *	12.2 (11.4-13.0) *	18.3 (17.6-19.0) *	17.8 (16.7-18.9) *
Hypertension	66.6 (65.9-67.3)	71.8 (69.4-74.2) *†	68.1 (66.0-70.2) †	90.1 (89.4-90.8) *	70.1 (69.3-70.9) *	74.4 (73.2-75.6) *

Dyslipidemia	50.9 (50.2-51.6)	61.5 (58.9-64.1) *	59.9 (57.6-62.2) *	53.2 (52.0-54.4) *	91.0 (90.5-91.5) *	52.3 (50.9-53.7)
Nonalcoholic fatty liver disease	17.4 (16.8-18.0)	31.6 (29.1-34.1) *†	21.1 (19.2-23.0) *†	19.7 (18.7-20.7) *	19.2 (18.5-19.9) *	20.0 (18.9-21.1) *
Diabetes complications						
Retinopathy	8.0 (7.6-8.4)	13.4 (11.6-15.2) *†	8.4 (7.1-9.7) †	11.2 (10.4-12.0) *	9.6 (9.1-10.1) *	8.7 (7.9-9.5)
Neuropathy	19.2 (18.6-19.8)	45.6 (42.9-48.3) *†	26.0 (24.0-28.0) *†	22.9 (21.9-23.9) *	23.7 (22.9-24.5) *	23.7 (22.5-24.9) *
Nephropathy	15.7 (15.2-16.2)	24.5 (22.2-26.8) *†	17.1 (15.4-18.8) †	22.5 (21.5-23.5) *	16.4 (15.7-17.1)	15.3 (14.3-16.3)
Smoking	21.0 (20.4-21.6)	25.5 (23.1-27.9) *	23.2 (21.3-25.1) *	23.1 (22.0-24.2) *	22.6 (21.8-23.4) *	23.7 (22.5-24.9) *
BMI, mean (SD)	28.5 (4.9) [28.4-28.6]	30.2 (5.4) *† [29.9-30.5]	29.6 (5.2) *† [29.4-29.8]	28.7 (4.9) [28.6-28.8]	28.6 (4.9) [28.5-28.7]	28.7 (4.9) [28.6-28.8]
Laboratory values, mean (SD)						
HbA1c, %	7.7 (1.8) [7.7-7.7]	8.1 (2.0) [8.0-8.2] *†	7.9 (1.8) *† [7.8-8.0]	7.7 (1.8) [7.7-7.7]	7.8 (1.8) * [7.8-7.8]	8.0 (1.9) * [7.9-8.1]
LDL-C, mmol/L	2.8 (1.0) [2.8-2.8]	2.6 (0.9) *† [2.6-2.6]	2.7 (0.9) *† [2.7-2.7]	2.7 (1.0) * [2.7-2.7]	2.7 (1.0) * [2.7-2.7]	2.7 (1.0) * [2.7-2.7]
HbA1c < 7%	41.1 (40.4-41.8)	33.5 (31.0-36.0) *	36.6 (34.4-38.8) *	41.7 (40.5-42.9)	32.0 (31.1-32.9) *	36.2 (34.9-37.5) *
LDL-C < 1.8	14.6 (14.1-15.1)	18.0 (15.9-20.1) *†	14.9 (13.3-16.5) †	16.8 (15.9-17.7) *	17.4 (16.7-18.1) *	19.7 (18.6-20.8) *
LDL-C < 1.4	4.3 (4.0-4.6)	5.8 (4.5-7.1) *	4.3 (3.4-5.2)	4.9 (4.4-5.4)	5.3 (4.9-5.7) *	6.3 (5.6-7.0) *

Abbreviations: GLP-1 RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose cotransporter-2 inhibitors; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.

*: the overall group as control group, $P < 0.05$.

†: the comparison was between GLP-1 RA and SGLT-2i, $P < 0.05$.

‡: the analysis was conducted in patients with ASCVD.

Patients with a moderate-intensity statins were more likely to have coronary (85.8% vs 80.5%) or cerebrovascular: (26.7% vs 22.2%) disease compared to the overall cohort. Patients prescribed a moderate-intensity statins, compared with the overall cohort, had a greater burden of hypertension (70.1% vs 66.6%), dyslipidemia (91.0% vs 50.9%) (Table 1).

Compared with the overall cohort, patients prescribed an aspirin were younger (mean age: 65.4 years vs 66.3 years), were more likely to be men (63.3% vs 56.1%), were more likely to be born in the fourth quarter (31.4% vs 29.2%). Patients prescribed an aspirin, compared with the overall cohort, had a greater burden of ASCVD (79.3% vs 48.6%), hypertension (74.4% vs 66.6%), and diabetic neuropathy (23.7% vs 19.2%) (Table 1).

Extent of Evidence-based Therapy Use

Overall, 3,048 patients (17.6%) were received no evidence-based cardiovascular benefit medications, while 4,772 patients (27.6%) received 1 medication, 5,356 patients (30.9%) received 2 medications, 3,313 patients (19.1%) received 3 medications, and 831 patients (4.8%) received 4 medications (Figure 3). Patients were divided into low (0 or 1 point), and high (2 to 4 points) groups based on their scores. Compared with patients with low evidence-based therapy scores, those with high scores were younger (mean age: 66.0 years vs 66.6 years), were more likely to be men (59.4% vs 52.1%), and more likely to be born in the fourth quarter (30.3% vs 28.1%).

Patients with high composite scores, compared with those with low scores, were less likely to be in the high risk of ASCVD group (38.5% vs 67.0%), had a higher burden of heart failure (21.1% vs 10.6%), hypertension (76.9% vs 54.0%) and dyslipidemia (58.9% vs 41.3%), and had a higher prevalence of diabetes chronic complications (retinopathy: 10.0% vs 5.5%; neuropathy: 24.9% vs 12.3%; nephropathy: 18.6% vs 12.2%). Compared to the patients with high risk of ASCVD, patients with ASCVD had a lower prevalence of low scores (30.7% vs 58.8%), and a higher prevalence of high scores (69.5% vs 41.0%) (Table 2).

Table 2. Patient characteristic at baseline, mean (SD) or n (%) by evidence-based therapy score.

	Evidence-based therapy score, % (95% CI)		
Patient characteristics	0-1 (N = 7820)	2-4 (N = 9500)	*p* value
Age, mean (SD) [95% CI], y	66.6 (10.2) [66.4-66.8]	66.0 (10.2) [65.8-66.2]	<□0.001
Sex			
Men	52.1 (51.0-53.2)	59.4 (58.4-60.4)	<□0.001
Women	47.9 (46.8-49.0)	40.6 (39.6-41.6)	<□0.001
Birth quarter			0.018
1	23.0 (22.1-23.9)	22.2 (21.4-23.0)	
2	22.7 (21.8-23.6)	22.0 (21.2-22.8)	
3	26.2 (25.2-27.2)	25.5 (24.6-26.4)	
4	28.1 (27.1-29.1)	30.3 (29.4-31.2)	
High risk of ASCVD	67.0 (66.0-68.0)	38.5 (37.5-39.5)	<□0.001
Comorbidities			
Heart failure	10.6 (9.9-11.3)	21.1 (20.3-21.9)	<□0.001
Hypertension	54.0 (52.9-55.1)	76.9 (76.1-77.7)	<□0.001
Dyslipidemia	41.3 (40.2-42.4)	58.9 (57.9-59.9)	<□0.001
Nonalcoholic fatty liver disease	13.3 (12.5-14.1)	20.7 (19.9-21.5)	<□0.001
Diabetes complications			

Retinopathy	5.5 (5.0-6.0)	10.0 (9.4-10.6)	<□0.001
Neuropathy	12.3 (11.6-13.0)	24.9 (24.0-25.8)	<□0.001
Nephropathy	12.2 (11.5-12.9)	18.6 (17.8-19.4)	<□0.001
Smoking	18.3 (17.4-19.2)	23.2 (22.4-24.0)	<□0.001
BMI, mean (SD)	28.1 (4.7) [28.0-28.2]	28.9 (5.3) [28.8-29.0]	<□0.001
Laboratory values, mean (SD)			
HbA1c, %	7.7 (1.9) [7.7-7.7]	7.9 (1.9) [7.8-7.9]	<□0.001
LDL-C, mmol/L	2.9 (1.0) [2.9-2.9]	2.7 (1.0) [2.7-2.7]	<□0.001
HbA1c < 7%	44.5 (43.4-45.6)	38.5 (37.5-39.5)	<□0.001
LDL-C < 1.8	10.9 (10.2-11.6)	17.7 (16.9-18.5)	<□0.001
LDL-C < 1.4	3.1 (2.7-3.5)	5.2 (4.8-5.6)	<□0.001

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.

DISCUSSION

In our cohort of patients with T2DM and established or high risk of ASCVD, we demonstrated that overall usage of evidence-based cardiovascular preventive therapies between 2018 and 2023. The study has several important findings. First, the overall antihyperglycemic agents with proven cardiovascular benefits use was 7.6% for GLP-1 RA, and 10.5% for SGLT2i. The utilization rates were 35.5% for ACEI/ARB, 66.3% for moderate-intensity statins, and 28.7% for aspirin. Second, the use of GLP-1 RA, SGLT2i, ACEI/ARB, moderate-intensity statins, and aspirin was higher in patients with ASCVD than in those with high risk of ASCVD. Third, approximately

half of patients received no or 1 evidence-based cardiovascular benefit medication, and fewer than 1 in 20 patients received all 4 medications.

Optimal medical treatment including cardioprotective glucose-, blood pressure-, lipid-lowering, and antiplatelet pharmacotherapy, is important for the prevention of cardiovascular in patients with T2DM and established or high risk of ASCVD. But these data indicated that the overall utilization of evidence-based cardiovascular preventive therapies in our population was lower than expected, particularly for GLP-1 RA and SGLT2i. The findings that 14.0% of patients in our study prescribed either a GLP-1 RA or SGLT2i (GLP-1 RA: 7.6%, SGLT2i: 10.5%) are consistent with those of recent studies conducted in the US and Belgian.[22-24] Fortunately, our study found that the use of both GLP-1 RA and SGLT2i increased gradually from 2018 to 2023. However, as recently as 2023, two glucose-lowering therapies without proven cardiovascular benefit, namely alpha-glucosidase inhibitors and DPP-4i, continue to be used more frequently than either GLP-1 RA or SGLT2i.

As we known, GLP-1 RA and SGLT2i both have demonstrated substantial benefits on major adverse cardiovascular events in those with T2DM and ASCVD.[25,26] Based on these data, the ADA has recommended GLP-1 RA and SGLT2i as first-line agents for patients with T2DM and ASCVD after metformin since 2019.[27] In 2023, the ADA recommended that clinicians consider prescribing GLP-1 RA and SGLT2i prior to metformin for patients with T2DM and established or high risk of ASCVD.[28] In the wake of these updates, the use of GLP-1 RA and SGLT2i both slightly increased from 2018 through 2019, followed by a more than 3-fold from 2019 to 2023. Despite these

improvements, GLP-1 RA and SGLT2i remained to be used less frequently than alpha-glucosidase inhibitors or DPP-4i.

A plethora of data support ACEIs or ARBs as first-line agents for hypertension in diabetes with ASCVD. Our study suggested that 35.5% of patients were prescribed ACEI/ARB, which is lower than that reported in contemporary registry cohorts.[16] The use of ACEI/ARB increased gradually from 2018 to 2023 yet remained lower than calcium channel blockers. What is worse is that an ACEI/ARB usage is only around 30.9% in T2DM patients with high risk of ASCVD. The finding that 66.3% of patients in this study were prescribed a moderate-intensity statins is consistent to findings from a US National Patient-Centered Clinical Research Network population from 2020 to 2021, which reported that only 58.6% of patients were receiving a statin.[19] But, in patients with T2DM and high risk of ASCVD, the use of moderate-intensity statins was only 52.3%. Our study indicated that the rates of aspirin use in patients with T2DM and established or high risk of ASCVD are concerning. In this context, these new data raise concerns that the use of evidence-based therapies for pharmaceutical treatments is far below expectations for practical application, despite the strengthening of guideline recommendations in the years prior to our study window.

As our study demonstrated, almost half of the patients were receiving no or 1 evidence-based therapy with proven cardiovascular benefit, and fewer than 1 in 20 patients were receiving all 4. The usage of evidence-based therapy in T2DM patients with high risk of ASCVD is lower than patients with ASCVD. Given that our cohort,

T2DM patients with established or high risk of ASCVD remain undertreated with evidence-based therapies.

Addressing these gaps in optimal pharmacotherapy is pivotal to improve patient outcomes. Reasons for continued underuse of these evidence-based therapies are likely multifactorial and include the relatively higher cost and out-of-pocket cost of new therapies as well as clinical inertia by prescribing physicians. For example, the use of GLP-1 RA rates doubled from 2020 through 2021, when the semaglutide was covered by health insurance in China. A similar trend was observed for SGLT2i, when the empagliflozin and dapagliflozin was covered by health insurance in 2020, the usage rates of these drugs doubled from 2019 to 2020. Therapeutic inertia within the realm of CVD prevention is a well-established barrier to widespread and consistent implementation of novel pharmacotherapeutic advances.[29] Herein, we observed slightly higher HbA1c levels and had a lower percentage of patients achieved HbA1c < 7% among those treated with GLP-1 RA and SGLT2i. These agents remained to be used less frequently than metformin or alpha-glucosidase inhibitors. This could imply that GLP-1 RA and SGLT2i were not considered as first-line therapeutic in T2DM individuals with high cardiovascular risk by clinicians.

There are several strengths and limitations to this study. The primary strength of this study is that we used routinely collected medical institution data. As such, the usage of evidence-based therapy was higher in tertiary hospitals than primary healthcare settings, and very likely reflect current practices in China. However, there are some limitations in this study. The first is that the present study was a retrospective study

from a single institution data with the inherent limitations of a retrospective design. Of special note, our study sample consisting almost entirely of participants of Asian ethnicity, thus study results may therefore not apply to other races. Second, an evaluation of adverse events was not included in our objectives because the validity of extracting adverse event information is not yet confirmed. Finally, pharmacy claims data suggest that switching agents is common. However, the proportion of patients who switching from cardiovascular evidence-based therapies to other noncardiovascular agents was not quantified in this study.

CONCLUSIONS

In conclusion, it is particularly concerning that less than two-fifth were prescribed an ACEI or ARB, two-third were prescribed a moderate-intensity statins, and only one-third were prescribed an aspirin, all of which are inexpensive and well-tolerated. Furthermore, over 1 in 6 patients did not receive any evidence-based therapies, and only 1 in 20 patients received all 4 evidence-based medications. Despite the room for improvement, our findings support cautious optimism around the uptake of these agents in clinical practice, the rates of cardiovascular evidence-based therapies increased annually from 2018 to 2023, especially for GLP-1RA and SGLT2i, which quadruple from 2018 to 2023. To continue this momentum, creative implementation science approaches will be necessary to further increase the use of these safe and effective medications in T2DM individuals with established or high risk of ASCVD.

FOOTNOTES

Contributors: All authors conceived and designed the study. YT P and JW Y

acquired the data. ZJ Z and ZY W analyzed and interpreted the data. JQ T and YH L wrote the manuscript, and all authors critically revised the manuscript. JQ T supervised the study and is the guarantor. All authors approved the final version of the manuscript and are accountable for its accuracy.

Funding: This work was supported by the Medical and Health Guidance Projects of Xiamen, China (Grant No.3502Z20224ZD1106).

Competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability statement

The administrative and clinical research databases used in this study are accessible to other researchers by contacting the corresponding author. The research data and data derivatives cannot be shared outside of the terms of these agreements.

References

1. Yun JS, Ko SH. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. *Metabolism*. Oct 2021;123:154838.

2. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. *Cardiovasc Diabetol*. Jun 8 2018;17(1):83.

3. Bancks MP, Ning H, Allen NB, et al. Long-term Absolute Risk for Cardiovascular Disease Stratified by Fasting Glucose Level. *Diabetes Care*. Mar 2019;42(3):457-465.

4. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. *Lancet*. Jul 17 2021;398(10296):262-276.

5. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. Jul 13 2019;394(10193):121-130.

6. Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. Aug 29 2019;381(9):841-851.

7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. Nov 10 2016;375(19):1834-1844.

8. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. Jul 28 2016;375(4):311-22.

9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. Aug 17 2017;377(7):644-657.

10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. Jan 24 2019;380(4):347-357.

11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. Nov 26 2015;373(22):2117-28.

12. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive Management of

Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. *Circulation*. Mar 2022;145(9):e722-e759.

13. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. Sep 7 2021;42(34):3227-3337.

14. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. *Diabetes Care*. Jan 1 2025;48(Supplement_1):S207-s238.

15. Society. CD. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)]. *Chin J Diabetes Mellitus*. April 2021;13(4):315-409.

16. Arnold SV, de Lemos JA, Rosenson RS, et al. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. *Circulation*. Aug 13 2019;140(7):618-620.

17. Nanna MG, Kolkailah AA, Page C, Peterson ED, Navar AM. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice. *JAMA Cardiol*. Jan 1 2023;8(1):89-95.

18. Nelson AJ, Ardissino M, Haynes K, et al. Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. *J Am Heart Assoc*. Jan 19 2021;10(2):e016835.

19. Nelson AJ, O'Brien EC, Kaltenbach LA, et al. Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. *JAMA Netw Open*. Feb 1 2022;5(2):e2148030.

20. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. *Diabetes Care*. Jan 1 2025;48(Supplement_1):S181-s206.

21. Xiao Y, Yu B, Chao C, et al. Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition). *J Transl Int Med*. Sep 2024;12(4):325-343.

22. King A, Tan X, Dhopeshwarkar N, et al. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. *BMJ Open Diabetes Res Care*. Oct 4 2024;12(5).

23. Raat W, Mamouris P, Mathieu C, Goderis G, Vaes B. Trends in type 2 diabetes medication use and guideline adherence in Belgian primary care (2019-2023). *Prim Care Diabetes*. Oct 31 2024.

24. Shin JI, Xu Y, Chang AR, et al. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. *J Am Coll Cardiol*. Aug 20 2024;84(8):683-693.

25. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet*. Jan 5 2019;393(10166):31-39.

26. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. *Circulation*. Apr 23 2019;139(17):2022-2031.

27. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. *Diabetes Care*. Jan 2019;42(Suppl 1):S103-s123. doi:10.2337/dc19-S010

28. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. *Diabetes Care*. Jan 1 2023;46(Suppl 1):S140-s157.

29. Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. *J Am Coll Cardiol*. Oct 1 2019;74(13):1728-1731.

Figure Legends

Figure 1. Trends in evidence-based therapy use among T2DM patients with established or high risk of ASCVD.

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; GLP-1 RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose cotransporter-2 inhibitors.

Figure 2. Evidence-based therapy use among T2DM patients with established or high risk of ASCVD.

Abbreviations: GLP-1 RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose cotransporter-2 inhibitors; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers.

Note: Evidence-based therapy composite score was scored as 0, no evidence-based therapies; 1, 1 evidence-based therapy; 2, 2 evidence-based therapies; 3, 3 evidence-based therapies and 4, 4 evidence-based therapies. Low scores were 0- or 1-point, high scores were 2 to 4 points.

Figure 3. Evidence-based therapy composite score.

Note: Evidence-based therapy composite score was scored as 0, no evidence-based therapies; 1, 1 evidence-based therapy; 2, 2 evidence-based therapies; 3, 3 evidence-based therapies and 4, 4 evidence-based therapies.


80
60
40
20
0
Medication use, %
2018
2019
2020
2021
2022
2023
Year
Stain
ACEI/ARB
Aspirin
GLP-1 RA/SGLT-2i
SGLT-2i
GLP-1 RA


80
70
60
50
40
30
20
10
0
GLP-1 RA
SGLT-2i
GLP-1 RA/SGLT-2i
ACEI/ARB
moderate-intensity statins
Aspirin
Low scores
High scores
ASCVD
High risk of ASCVD


Composite Score for Evidence-based Therapy
0
1
2
3
4
0
5
10
15
20
25
30
35
Percentage, %